• Traverse
    • Timmerman Traverse for Damon Runyon – Sierras 2026
    • Past Climbs (2018-2026)
  • The Long Run Podcast
  • About
    • Speaking
    • Podcast
    • Events
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
Biotech Leaders Get It
  • Traverse
    • Timmerman Traverse for Damon Runyon – Sierras 2026
    • Past Climbs (2018-2026)
  • The Long Run Podcast
  • About
    • Speaking
    • Podcast
    • Events
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
31
Oct
2016

How Leaders Can Create a Resilient Culture, Like Pete Carroll’s Seahawks

/
Luke Timmerman
/
0
/
All, People, The Edge
31 Oct 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
28
Oct
2016

Amgen Increases Prices (Again), Humana Flexes Muscle, and MIT Starts a $150M Engine

/
Luke Timmerman
/
0
/
All
28 Oct 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
25
Oct
2016

The Next Voice You Hear Will Be Dr. Alexa’s

/
Lisa Suennen
/
0
/
All, People, Strategy
25 Oct 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
21
Oct
2016

Bernie Fumes at Ariad, Alkermes Depression Drug Rebounds & ASHG Notes

/
Luke Timmerman
/
0
/
All, Genomics
21 Oct 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
17
Oct
2016

Value Frameworks: Can they Provide Value for Patients?

/
Leora Schiff
/
1
/
All, Payers
17 Oct 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
14
Oct
2016

ESMO Recap, Illumina’s Misfire, and Mylan’s Monster $465M Medicaid Settlement

/
Luke Timmerman
/
0
/
All
14 Oct 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
10
Oct
2016

The BCG Alumni: Where Are They Wielding Influence in Biotech & Pharma?

/
Luke Timmerman
/
1
/
All, People
10 Oct 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
7
Oct
2016

Alnylam’s Stumble, Theranos Strings ‘Em Along, & Sarepta’s Deal Spree

/
Luke Timmerman
/
0
/
All
07 Oct 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
3
Oct
2016

Is Your Biotech PR Firm Delivering Signal, or Noise?

/
Luke Timmerman
/
1
/
All, Strategy
03 Oct 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
30
Sep
2016

Gilead’s Rough Week, Grail Poaches a Data Star, & Kite Passes a Big CAR-T Trial

/
Luke Timmerman
/
0
/
All
30 Sep 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
27
Sep
2016

Google Translate Star Leaves Venter’s Human Longevity to Join Illumina’s Grail

/
Luke Timmerman
/
0
/
All, Cancer, Diagnostics, People
27 Sep 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
26
Sep
2016

How Much for an Antibiotic that Could Help Hillary? Cempra Tests Fair Price

/
Luke Timmerman
/
0
/
All, The Edge
26 Sep 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
22
Sep
2016

Sarepta’s Controversial Victory, Allergan’s Buying Spree, & GSK’s History-Making CEO  

/
Luke Timmerman
/
0
/
All, Politics
22 Sep 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
13
Sep
2016

What Phil Sharp Thinks of ‘Hood’ + 3 Book Events in Boston

/
Luke Timmerman
/
0
/
All, Genomics, People
13 Sep 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
12
Sep
2016

Saunders Reminds an Industry of Its Purpose. Who’s Listening?

/
Luke Timmerman
/
1
/
All, Politics, The Edge
12 Sep 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
9
Sep
2016

Reflections from Yellowstone, EpiPen’s Foul Aftermath, and Saunders Steps Up

/
Luke Timmerman
/
0
/
All
09 Sep 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
29
Aug
2016

Can Biotech and Pharma Be Restrained in an Unrestrained World?

/
Luke Timmerman
/
3
/
All, Politics, The Edge
29 Aug 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
26
Aug
2016

EpiPen Pricing Fury, Pfizer’s $14B Megabid for Medivation & Denali Grabs $130M

/
Luke Timmerman
/
1
/
All, Strategy
26 Aug 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
Aug
2016

Illumina Takeout? Ha!, Portola Stumbles, and NYT Biotech Ace Moves On

/
Luke Timmerman
/
0
/
All
19 Aug 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
15
Aug
2016

Watching the Watchdog: How Does ICER Determine ‘Fair’ Prices for Drugs?

/
Leora Schiff
/
1
/
All, Drugs, Payers
15 Aug 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
‹ Previous 1 … 71 72 73 74 75 … 84 Next ›

Get In-depth Biotech Coverage with Timmerman Report.

Individual Subscription

Group Subscription

Or: Sign in to your account

Your account

Sign in

What Readers Are Saying

testimonial

View More Testimonials ➛

© Copyright 2026, TimmermanReport.com
Privacy Policy | Terms of Use
Custom WordPress site by: Perception Builder